Endo is a diversified pharmaceutical company with a history dating back to 1920 when it was founded as Intravenous Products of America, Inc. in New York City. The company later changed its name to Endo Products and eventually became part of DuPont, expanding its capabilities in pharmaceutical research and marketing. In the 1990s, it evolved through a partnership with Merck and reestablished as Endo Laboratories LLC focused on generic medications. In 1997, Endo Pharmaceuticals Inc. was formed by executives purchasing its generic and branded medicines.

Today, Endo focuses on developing and delivering complex, life-enhancing pharmaceutical products primarily in the areas of urology, orthopedics, endocrinology, and sterile injectables for hospitals and health systems. It combines a rich manufacturing legacy with ongoing innovation in specialty medicines, sterile injectables, and generics. The company aims to reduce complexity in healthcare delivery by providing high-quality therapies and seamless experiences for patients and healthcare providers.

Endo operates a modern 90,000-square-foot facility in Rochester, Michigan, supporting its manufacturing and research efforts, building on its century-long legacy. The company works closely with clinical trial sites globally to advance medical innovations and discover treatments addressing unmet patient needs. Its portfolio includes specialty medicines empowering various specialists, sterile injectable products for hospital use, and a range of generics distributed through multiple pharmacy channels.

Endo’s mission is driven by collaboration and a quality mindset to bring forward pharmaceutical solutions that make a real difference in patient care and health outcomes, emphasizing patient focus and research excellence.

The company is headquartered in Chesterbrook, Pennsylvania, United States, and is recognized as a significant player in specialty healthcare and pharmaceutical manufacturing.